Is BPC-157 Safe? Safety Profile 2026 — PeptidePrices

Q: Is BPC-157 safe?

BPC-157 has a safety rating of 7/10 in our methodology — good. Extensive preclinical safety; 3 small human studies with zero adverse events; naturally derived gastric peptide

Q: Is BPC-157 FDA approved?

FDA status: Not FDA-approved (Category 2). PeptidePrices does not sell or recommend any compound for human use; this information is for research-context only.

Q: Where can I find verified BPC-157?

PeptidePrices tracks live prices and COA verification status across 30+ vendors. See our cheapest BPC-157 listings for prices ranked by COA tier and $/mg.

Safety Profile

BPC-157

Updated today

Cellular Peptide

7/10Good

How we score compound safety →

Primary use: Tissue repair research

Regulatory Status

Not FDA-approved (Category 2)

Safety Summary

Extensive preclinical safety
3 small human studies with zero adverse events
naturally derived gastric peptide

BPC-157's 7/10 rating reflects mixed evidence — some clinical data and a meaningful research base, but enough open questions that researchers should weight personal risk tolerance heavily. Long-term safety in the population segment most likely to use this compound (off-label) is the area with the thinnest published evidence. Researchers often consider GHK-Cu and TB-500 as alternatives in the same category — see the related-compounds section below for safety comparisons.

Molecular Profile

TypeSynthetic pentadecapeptide

Molecular Weight1,419.5 g/mol

Amino Acids15

CAS Number137525-51-0

SequenceGEPPPGKPADDAGLV

FormulaC₆₂H₉₈N₁₆O₂₂

Storage

Lyophilized−20°C, stable

Reconstituted2–8°C, within 30 days

Room temp stable short-term
Protect from light
Resists enzymatic degradation
Gastric stability: 24+ hours

Related Compounds

Methodology

How we rate peptide safety

Every compound in our index gets a 1–10 safety score based on four weighted factors. The score reflects known research-use risk — not medical advice.

40% — Clinical evidence. Volume of peer-reviewed trials, sample sizes, duration, and consistency of outcomes. FDA-approved compounds anchor the top end (8–10); preclinical-only compounds cap at 6.
30% — Adverse-event profile. Severity and frequency of reported side effects, including GI events, cardiovascular signals, hypoglycemia, and long-term organ effects.
20% — Regulatory status. FDA approval, EMA approval, or status in active clinical trials. Compounds under safety warnings are penalized.
10% — Community-reported outcomes. Reddit, forum, and published case-report signal beyond formal trials. Used as a late-stage tiebreaker, not a leading factor.

9–10Well-studied, FDA-approvedLarge-trial evidence, established long-term safety. Examples: semaglutide, tesamorelin at approved doses.

7–8Mostly safe, some caveatsPhase 2/3 evidence or long community track record with known manageable side effects. Routine monitoring recommended.

5–6Mixed dataLimited clinical trials, mostly community/preclinical data. Real but uncertain risk profile.

3–4Caution advisedKnown side-effect patterns, thin safety data, or compounds under active regulatory scrutiny.

1–2Significant risk signalsDocumented serious adverse events (cardiovascular, hepatotoxicity, contamination) or withdrawn regulatory status.

Related compounds

Other compounds researchers compare with BPC-157

Full BPC-157 profile Cheapest BPC-157 deals

Safety ratings are derived from published clinical data, FDA approval status, and community-reported outcomes. They are not medical advice. Always consult a healthcare professional before using any research compound.